2359.HK
603259.SHG
Ribo does biotech

Pharmaceutical outsourcing giant WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) announced on Thursday it will raise HK$7.65 billion ($975 million) by placing around 73.8 million new Hong Kong-listed shares at HK$104.27 per share, representing a 6.9% discount to the stock’s previous closing price of HK$112. The new shares account for about 16.01% of the company’s enlarged capital for its Hong Kong-listed stock and 2.51% of its total issued share capital.

WuXi AppTec said around 90% of the proceeds will be used to accelerate expansion of its global footprint and expand production capacity, while the remaining 10% will go toward general corporate purposes.

The share placement comes shortly after the company reported strong first-half results. Revenue for the six months through June rose 20.64% year-on-year to 20.8 billion yuan, while its net profit surged 95.46% to 8.29 billion yuan.

WuXi AppTec’s stock opened lower on Thursday and closed at HK$107.8 by the midday break, down 3.75%. The stock is up 90% year-to-date.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Geneplus IPO

Geneplus locks onto targeted medicine for IPO pitch

After a post-Covid earnings dip, the company is seeking a stable future as a provider of data and diagnostics for precision medicine and disease prevention   Key Takeaways: The company’s…

Hong Kong’s IPO rally under scrutiny, as ZTE hits new U.S. headwinds

Hong Kong's stock regulator has warned IPO underwriters over the declining qualiy of new listing applications. Is this a red flag for the city's booming IPO market, or just the usual regulatory caution? And the U.S. could fine telecoms equipment maker ZTE $1 billion for bribery in Brazil. Why does Washington think it can force ZTE to pay such a large amount?